奥谷胱甘肽(Oxiglutatione) - 在研适应症：缺氧，肝病，中毒_专利_临床

概要

基本信息

药物类型

小分子化药

别名

GSSG、Glutathione disulphide、Oxidized glutathione

+ [6]

靶点-

作用机制-

治疗领域

消化系统疾病其他疾病

在研适应症

缺氧肝病中毒+ [1]

非在研适应症-

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

重庆药友制药有限责任公司Alcon Laboratories, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1991-10-04),

眼科外科手术

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C20H32N6O12S2

InChIKeyYPZRWBKMTBYPTK-BJDJZHNGSA-N

CAS号27025-41-8

关联

3

项与奥谷胱甘肽相关的临床试验

JPRN-UMIN000015962 / CompletedIIT

A study of the effectiveness and safety of pars plana vitrecotmy with subretinal oxiglutatione injection for the treatment of refractory macular edema - Subretinal oxiglutatione injection for the treatment of macular edema

开始日期2015-01-05

申办/合作机构-

JPRN-UMIN000015296 / RecruitingIIT

Evaluation of the efficacy of vitrectomy with Subretinal oxiglutatione intraocular irrigating solution injection for subretinal hemorrhages - Vitrectomy with Subretinal oxiglutatione intraocular irrigating solution injection for subretinal hemorrhages

开始日期2014-03-01

申办/合作机构-

JPRN-UMIN000016712 / RecruitingIIT

Evaluation of the efficacy of vitrectomy with Subretinal oxiglutatione intraocular irrigating solution injection for macula edema - Evaluation of the efficacy of vitrectomy with Subretinal oxiglutatione intraocular irrigating solution injection for macula edema

开始日期2014-03-01

申办/合作机构-

100 项与奥谷胱甘肽相关的临床结果

登录后查看更多信息

100 项与奥谷胱甘肽相关的转化医学

登录后查看更多信息

100 项与奥谷胱甘肽相关的专利（医药）

登录后查看更多信息

219

项与奥谷胱甘肽相关的文献（医药）

2024-07-08·Annals of Work Exposures and Health

Effects of the combined exposure to chemicals and unusual working hours

Review

作者: Bråtveit, Magne ; Lie, Jenny-Anne S ; Zienolddiny-Narui, Shan

AbstractObjectiveBoth exposure to occupational chemicals and to unusual working hours have well documented effects on health. Determination of occupational exposure limits is, however, usually based on chemical-only exposure and assumes an 8-h workday, 5 days/week and a 40-h work week. A significant proportion of the workforce is exposed to chemicals while working in other work schedules. This review thus aimed to synthesize and evaluate the scientific support for a combined effect of unusual working hours and chemical exposure and, if possible, give recommendations for OEL adjustments to account for unusual working hours.MethodsThe search for articles was made as part of the preparation of a report for the Nordic Expert Group for Criteria Documentation of Health Risks from Chemicals. In this report, unusual working hours were categorized as shift work or extended (>8 h) working hours. Inclusion criteria were observational studies in the English language published up to November 2021 in peer-reviewed journals, with explicit metrics of exposure (chemicals and unusual working hours) and of health outcome, and which explicitly tested the association between exposure and outcome. Search engines of seven databases were used.ResultsOf the initially 15 400 identified papers, 9 studies published between 1985 and 2021 met the inclusion criteria, 7 of which showed significant associations. Results from a few of the studies, i.e. regarding effects of dust and endotoxin on lung function, effects of acetone on sleep quality and tiredness, effects of carbon disulphide on coronary artery disease and effects of chemicals on spontaneous abortion, suggested more pronounced effects during night shifts compared to during day shifts.DiscussionThe reviewed data is considered insufficient to conclude on recommendations for OEL adjustment for shift work. Suggested areas of future studies are mentioned.ConclusionFurther studies about the effects of the combined exposure to unusual working hours and chemical exposure are essential for risk assessment, and for recommendation of potential OEL adjustments. What is important about this paper? Effects of chemical agents at the workplace may depend not only on exposure level and duration but also on the time of exposure in relation to the circadian rhythm. This study reviewed the scientific support for a combined effect of unusual working hours and chemical exposure and revealed an obvious need for additional studies regarding the complex interplay of the two different exposures with respect to adverse health effects.

2024-05-01·International Journal of Biological Macromolecules

Study on synergistic mechanism of molybdenum disulfide/sodium carboxymethyl cellulose composite nanofiber mats for photothermal/photodynamic antibacterial treatment

Article

作者: Gao, Yujie ; Liu, Lei ; Yang, Yang ; Sun, Hengqiu ; Xu, Chenlu ; Qi, Dongming ; Yu, Dan ; Wu, Jindan ; Xu, Bingjie

Innovative antibacterial therapies using nanomaterials, such as photothermal (PTT) and photodynamic (PDT) treatments, have been developed for treating wound infections. However, creating secure wound dressings with these therapies faces challenges. The primary focus of this study is to prepare an antibacterial nanofiber dressing that effectively incorporates stable loads of functional nanoparticles and demonstrates an efficient synergistic effect between PTT and PDT. Herein, a composite nanofiber mat was fabricated, integrating spherical molybdenum disulfide (MoS₂) nanoparticles. MoS₂ was deposited onto polylactic acid (PLA) nanofiber mats using vacuum filtration, which was further stabilized by sodium carboxymethyl cellulose (CMC) adhesion and glutaraldehyde (GA) cross-linking. The composite nanofibers demonstrated synergistic antibacterial effects under NIR light irradiation, and the underlying mechanism was explored. They induce bacterial membrane permeability, protein leakage, and intracellular reactive oxygen species (ROS) elevation, ultimately leading to >95 % antibacterial activity against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), which is higher than that of single thermotherapy (almost no antibacterial activity) or ROS therapy (about 80 %). In addition, the composite nanofiber mats exhibited promotion effects on infected wound healing in vivo. This study demonstrates the great prospects of composite nanofiber dressings in clinical treatment of bacterial-infected wounds.

2024-01-02·Drug and Chemical Toxicology

Study on the acute toxicity of sodium taurocholate via zebrafish mortality, behavioral response, and NMR-metabolomics analysis

Article

作者: Ismail, Intan Safinar ; Abdulazeez, Isah ; Christianus, Annie ; Chong, Seok-Giok ; Mohd Faudzi, Siti Munirah

Sodium taurocholate (NaT) is a hydrophobic bile salt that exhibits varying toxicity and antimicrobial activity. The accumulation of BSs during their entero-hepatic cycle causes cytotoxicity in the liver and intestine and could also alter the intestinal microbiome leading to various diseases. In this research, the acute toxicity of sodium taurocholate in different concentrations (3000 mg/L, 1500 mg/L, 750 mg/L, 375 mg/L, and 0 mg/L) was investigated on four months old zebrafish by immersion in water for 96 h. The results were determined based on the fish mortality, behavioral response, and NMR metabolomics analysis which revealed LC50 of 1760.32 mg/L and 1050.42 mg/L after 72 and 96 h treatment, respectively. However, the non-lethal NaT concentrations of 750 mg/L and 375 mg/L at 96 h exposure significantly (p ≤ 0.05) decreased the total distance traveled and the activity duration, also caused surface respiration on the zebrafish. Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) revealed that the metabolome of the fish treated with 750 mg/L was discriminated from that of the control by PC1. Major significantly downregulated metabolites by NaT-induction include valine, isoleucine, 2-hydroxyvalerate, glycine, glycerol, choline, glucose, pyruvate, anserine, threonine, carnitine and homoserine. On the contrary, taurine, creatine, lactate, acetate and 3-hydroxybutyrate were upregulated suggesting cellular consumption of lipids, glucose and amino acids for adenosine triphosphate (ATP) generation during immune and inflammatory response. whereby these metabolites were released in the process. In conclusion, the research revealed the toxic effect of NaT and its potential to trigger changes in zebrafish metabolism.

1

项与奥谷胱甘肽相关的新闻（医药）

2022-08-23

·药研

为药企的多肽药物立项作参考

作者｜大小姐整理｜药研鉴于多肽类药物的品种特性，引起越来越多的药企关注，本文检索、搜集了国内外的信息，汇总如下。且根据目前市场情况，笔者推荐品种是，阿托西班、布舍瑞林、西曲瑞克、利拉鲁肽、奥谷胱甘肽。备注：仅供参考，项目品种的立项涉及多方面的考虑。------------THE END------------点击查看：投稿获丰厚稿费关注药研一路同行药研论坛：始终以为药品研发一线人员提供高质量、高性价比培训为第一宗旨。自成立以来，累计举办近50期药品研发类、注册类研讨班。据统计，中国医药工业百强企业中超过85%参加过药研收费类培训。截至2021年底，包括上海强生、辉瑞、阿斯利康、山德士、日本大冢、大鹏、卫材、小林制药、扬子江、恒瑞、正大天晴、东阳光、科伦、中科院等在内的2000余家企事业单位参加过药研线下论坛，得到业界普遍认可与好评，已成为制药领域知名高端培训品牌！药研公众号：自2016年成立以来持续为业内提供药物研发、生产和注册相关信息，目前药品研发领域关注用户约10万人！制药企业和研发机构关注量4000家。药研学院：截至2021年底，已同众多企业合作近60期直播课，观看量突破40万+，药研直播课聚焦药品研发相关主题，平均观看人数行业领先。商务合作：15911172616

100 项与奥谷胱甘肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00031	奥谷胱甘肽	V03AB	DB03310

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
缺氧	中国	重庆药友制药有限责任公司	1999-01-01
肝病	中国	重庆药友制药有限责任公司	1999-01-01
中毒	中国	重庆药友制药有限责任公司	1999-01-01
眼科外科手术	日本	Alcon Laboratories, Inc.	1991-10-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2023	N/A	-	-	Glutathione oxidized	鬱獵襯範齋鹽憲憲衊網(餘鹹蓋蓋鑰鑰網鹹遞齋) = 齋衊鬱鬱鹹積艱鑰齋繭築顧餘齋蓋網蓋夢蓋壓 (淵蓋廠簾衊遞鹹鑰願鹹 )	-	2023-06-01
				Raddeanin A	鬱獵襯範齋鹽憲憲衊網(餘鹹蓋蓋鑰鑰網鹹遞齋) = 鑰鏇憲顧獵選鹹鏇齋築築顧餘齋蓋網蓋夢蓋壓 (淵蓋廠簾衊遞鹹鑰願鹹 )
ARVO2006	N/A	-	-	Ascorbic Acid	襯鬱衊鬱繭築壓獵蓋願(鹽蓋鏇鏇窪獵壓窪鹹築) = 鹹廠鏇簾齋艱範蓋壓憲壓鏇選憲衊糧鏇獵淵製 (獵糧醖艱壓夢餘糧蓋積 )	-	2006-05-01
				BSS Plus and ascorbic acid solution	襯鬱衊鬱繭築壓獵蓋願(鹽蓋鏇鏇窪獵壓窪鹹築) = 鹽願鹹獵襯鏇鏇齋範鑰壓鏇選憲衊糧鏇獵淵製 (獵糧醖艱壓夢餘糧蓋積 )